Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043508 · ClinicalTrials.gov registry record
Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
A clinical trial of Genetic Mutation and MEN1, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT03043508: Active study of Genetic Mutation and MEN1, sponsored by M.D. Anderson Cancer Center.
NCT03043508 is a study of Genetic Mutation and MEN1 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03043508, a study of Genetic Mutation and MEN1, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: The primary objective of this study is to evaluate the effect of estrogen on the development of the PNET in MEN1 patients. The secondary objective is to evaluate the overall survival and disease specific survival in patients who have confirmed MEN1 with or without PNET and a pancreatic neuroendocrine tumor in relation to their hormone status. The secondary objective is to evaluate clinicopathologic features in relation to hormone status.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaire
- OTHER Chart Review
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-04-10 |
| Est. Completion | 2026-04-01 |
What the registry record for NCT03043508 still lists
NCT03043508 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 2 conditions, with Genetic Mutation appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire is the first listed.
NCT03043508 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03043508 about?
NCT03043508 is a clinical study titled "Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)". OBJECTIVES: The primary objective of this study is to evaluate the effect of estrogen on the development of the PNET in MEN1 patients. The secondary objective is to evaluate the overall survival and disease specific survival in patients who have confirmed MEN1 with or without PNET and a pancreatic...
What is the current status of trial NCT03043508?
This trial is currently active not recruiting. The enrollment target is 45 participants. The study started on 2015-04-10. Estimated completion is 2026-04-01.
What conditions does trial NCT03043508 study?
This clinical trial studies the following conditions: Genetic Mutation, MEN1.
What interventions are being tested in trial NCT03043508?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Chart Review (OTHER).
Who is sponsoring clinical trial NCT03043508?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03043508 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI